The PROMUS, Cypher and Endeavor Stents have previously been investigated in randomized clinical trials. Twelve-month data from the SPIRIT III Trial, presented in October 2007 at the Transcatheter Cardiovascular Therapeutics conference in Washington, confirmed earlier positive clinical results for the XIENCE V (PROMUS) Stent. This trial compared XIENCE V (PROMUS) with the market-leading TAXUS(R) Express2(TM) Paclitaxel-Eluting Stent, demonstrating non-inferiority in the primary endpoint of in-segment late loss at eight months with no safety concerns at 12 months.
Boston Scientific is the first company to offer European physicians and their patients a choice of two distinct drug-eluting stent platforms: TAXUS and PROMUS.
TAXUS and PROMUS are trademarks of Boston Scientific Corporation or its affiliates. XIENCE is a trademark of the Abbott Laboratories group of companies. Endeavor is a trademark of Medtronic Vascular Incorporated. Cypher is a trademark of Cordis Corporation, a Johnson & Johnson company.
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.
Cautionary Statement Regarding Forward Looking Statements
This press release contains forward-looking statements within the
meaning of Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements may be identified by words like "anticipate,"
"expect," "project," "believe," "plan," "estim
|SOURCE Boston Scientific Corporation|
Copyright©2008 PR Newswire.
All rights reserved